Alonso-Lerma, Borja
Jabalera, Ylenia http://orcid.org/0000-0003-1786-959X
Samperio, Sara
Morin, Matias http://orcid.org/0000-0002-7985-592X
Fernandez, Almudena http://orcid.org/0000-0002-4983-5362
Hille, Logan T. http://orcid.org/0000-0001-7515-124X
Silverstein, Rachel A.
Quesada-Ganuza, Ane
Reifs, Antonio
Fernández-Peñalver, Sergio
Benitez, Yolanda
Soletto, Lucia http://orcid.org/0000-0002-5768-5317
Gavira, Jose A.
Diaz, Adrian
Vranken, Wim http://orcid.org/0000-0001-7470-4324
Sanchez-Mejias, Avencia
Güell, Marc
Mojica, Francisco J. M. http://orcid.org/0000-0002-6660-4996
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Moreno-Pelayo, Miguel A. http://orcid.org/0000-0003-3839-5098
Montoliu, Lluis http://orcid.org/0000-0003-3941-1176
Perez-Jimenez, Raul http://orcid.org/0000-0001-7094-6799
Article History
Received: 24 May 2022
Accepted: 7 October 2022
First Online: 2 January 2023
Competing interests
: R.P.-J. and B.A.-L. are co-inventors on a patent application (European Patent Application EP21382474) filed by CIC nanoGUNE and licensed to Integra Therapeutics S.L. relating to work in this article. A.S.-M. and M.G. are cofounders of Integra Therapeutics S.L. B.P.K. is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies, including the HT-PAMDA method (WO2021151065). B.P.K. is a consultant for EcoR1 Capital and is an advisor to Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. The remaining authors declare no competing interests.